Kazazian Asset Management LLC purchased a new position in shares of Puma Biotechnology Inc (NYSE:PBYI) during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,393 shares of the biopharmaceutical company’s stock, valued at approximately $209,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Teacher Retirement System of Texas bought a new position in Puma Biotechnology in the 2nd quarter valued at $211,000. Renaissance Technologies LLC acquired a new stake in shares of Puma Biotechnology in the 1st quarter valued at $7,682,000. American International Group Inc. increased its stake in shares of Puma Biotechnology by 19.2% in the 1st quarter. American International Group Inc. now owns 16,931 shares of the biopharmaceutical company’s stock valued at $630,000 after buying an additional 2,733 shares during the period. Endurant Capital Management LP acquired a new stake in shares of Puma Biotechnology in the 1st quarter valued at $1,101,000. Finally, Swiss National Bank increased its stake in shares of Puma Biotechnology by 2.1% in the 1st quarter. Swiss National Bank now owns 54,730 shares of the biopharmaceutical company’s stock valued at $2,036,000 after buying an additional 1,100 shares during the period. Institutional investors and hedge funds own 80.98% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark and copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/2393-shares-in-puma-biotechnology-inc-pbyi-acquired-by-kazazian-asset-management-llc/1608270.html.

In other Puma Biotechnology news, insider Alan H. Auerbach sold 13,175 shares of the stock in a transaction dated Thursday, July 20th. The stock was sold at an average price of $94.73, for a total transaction of $1,248,067.75. Following the completion of the sale, the insider now directly owns 4,170,623 shares in the company, valued at approximately $395,083,116.79. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Richard Paul Bryce sold 15,000 shares of the stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $120.00, for a total value of $1,800,000.00. Following the sale, the senior vice president now owns 42,239 shares of the company’s stock, valued at $5,068,680. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 45,173 shares of company stock valued at $4,738,189. Company insiders own 22.70% of the company’s stock.

Puma Biotechnology Inc (PBYI) traded up 2.543% during midday trading on Wednesday, reaching $119.975. The company had a trading volume of 293,494 shares. The stock has a 50-day moving average price of $98.26 and a 200 day moving average price of $72.59. The company’s market capitalization is $4.46 billion. Puma Biotechnology Inc has a 12-month low of $28.35 and a 12-month high of $122.40.

Puma Biotechnology (NYSE:PBYI) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($2.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.78). Equities analysts forecast that Puma Biotechnology Inc will post ($8.67) EPS for the current year.

A number of equities research analysts have recently weighed in on PBYI shares. J P Morgan Chase & Co restated a “buy” rating on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Citigroup Inc. reiterated a “buy” rating and issued a $114.00 price target on shares of Puma Biotechnology in a report on Tuesday, July 18th. Stifel Nicolaus reiterated a “buy” rating and issued a $118.00 price objective (up from $105.00) on shares of Puma Biotechnology in a research report on Tuesday, July 18th. Zacks Investment Research upgraded Puma Biotechnology from a “hold” rating to a “buy” rating and set a $89.00 price objective for the company in a research report on Thursday, June 8th. Finally, Bank of America Corporation reiterated a “buy” rating and issued a $117.00 price objective (up from $100.00) on shares of Puma Biotechnology in a research report on Friday, July 21st. One research analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $112.70.

About Puma Biotechnology

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NYSE:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NYSE:PBYI)

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.